James Chan

Title: Innovations in Prostate Cancer Research by James Chan

Introduction

James Chan is an accomplished inventor based in Sugarland, TX (US). He has made significant contributions to the field of prostate cancer research through his innovative work. His research focuses on the role of protein factors derived from bone and prostate tissues in affecting prostate cancer.

Latest Patents

James Chan holds a patent titled "Bone and prostate-derived protein factors affecting prostate cancer." This patent highlights the role of a substantially purified human growth factor preparation, which contains a distinct polypeptide with an apparent molecular weight of about 220 kD. This polypeptide is distinct from basic fibroblast growth factor (bFGF), with the most active fraction also at approximately 220 kD. Additionally, a human growth factor polypeptide of 157 kD was identified in human bone marrow aspirates and from bone stromal cells through immunoblotting techniques. The research also identifies a PSA stimulating autocrine factor, PSAF, which can induce PSA expression and secretion, serving as an indicator of androgen-independent prostate cell growth. James Chan has 1 patent to his name.

Career Highlights

James Chan is affiliated with the University of Texas System, where he continues to advance his research in cancer biology. His work has garnered attention for its potential implications in understanding and treating prostate cancer.

Collaborations

James has collaborated with notable researchers in the field, including Leland W Chung and Christopher Logothetis. These collaborations have further enriched his research and contributed to the advancement of knowledge in prostate cancer.

Conclusion

James Chan's innovative research and patent contributions are vital in the ongoing fight against prostate cancer. His work not only enhances our understanding of the disease but also opens new avenues for potential treatments.